P-075 - Endoscopic treatment of type 3 gastric neuroendocrine tumor

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Neuroendocrine Tumours
Surgical Oncology
Radiation Oncology
Presenter H.M. Kim
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors H.M. Kim1, S.K. Lee2, K.J. Lee1, W.J. Lee3, S.J. Park4
  • 1Yonsei University Wonju College of Medicine, Wonju/KR
  • 2Yonsei University College of Medicine, Seoul/KR
  • 3National Cancer Center, Goyang/KR
  • 4Kosin University, Busan/KR



The treatment modality of type 3 gastric neuroendocrine tumor (NET) is radical gastrectomy, but small tumors have been treated by endoscopy recently although the endoscopic treatment of type 3 gastric NET has not been established. The aim of this study was to investigate prognosis of type 3 gastric NET after the endoscopic treatment.


The Korean Society of Gastrointestinal Cancer conducted the Korean Gastroenteropancreatic Neuroendocrine Tumor Registry in 2012. This registry is a retrospective database of gastroenteropancreatic neuroendocrine tumor collected from 16 hospitals between 2002 and 2012. From the registry data, gastric NET patients with normal serum gastrin level (<100 pg/mL) were selected for analysis.


A total of 14 patients with type 3 Gastric NET were treated by endoscopy. The median age was 53 years (range: 30-69). The median tumor size was 6 mm (range: 3-16 mm). The median serum gastrin level was 49.8 pg/mL (range: 0.05-98.0). The tumor was located in body (11, 78.6%) and fundus (3, 21.4%). According to the WHO 2010 classification, 11 (78.6%) patients had grade 1, and 3 (21.4%) patients had grade 2. After treatment, the median follow-up time was 14 months (range: 0-51), during when there was no recurrence of gastric NET.


Type 3 gastric NET with small size has been treated by endoscopy safely. This finding suggests that endoscopic treatment is an alternative modality to surgery in selected cases of type 3 gastric NET.